NASDAQ · AMIX

Autonomix Medical, Inc.

$2.92 -$0.58 (-16.57%) 1D After hours
Session Pulse Overnight session 1 mentions on Fri · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →

Key Metrics

$1.59M
Market cap
P/E · TTM
$0
Revenue · TTM
−$16.72M
Net income
EPS · TTM $-9.46
Dividend yield
Free cash flow −$12.29M
Beta · 1Y 1.77
EBITDA · TTM −$16.70M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Mar 18 high, the share price fell 70%.

    Peak close $9.64 on Mar 18; trough close $2.92 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -70%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 21
    The stock moved +18.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 21
  • May 20
    The stock moved +18.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 20

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.59M
Enterprise value
Shares outstanding543.0K
52-wk range$0.53 – $13.41
Avg volume · 20D1.1M
Net cash
Book value / share$3.34
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Autonomix Medical, Inc.
IPO dateJan 29, 2024
Employees11

Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -283.5% · 1,507.2%

Financial Health

Current ratio4.45
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.88M

Cash Flow · TTM

Operating CF −$12.28M
Capex −$10.00K
Free cash flow −$12.29M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-18.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-12-31 · computed by TickerWolf from SEC filings